BioCentury
ARTICLE | Top Story

Victoza reduces risk of CV events

March 5, 2016 1:23 AM UTC

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said diabetes drug Victoza liraglutide plus standard of care met the primary endpoint of significantly reducing cardiovascular risk vs. placebo plus SOC in the LEADER CV outcomes trial. The company said Victoza is the first glucagon-like peptide-1 (GLP-1) analog to show CV superiority to SOC in Type II diabetics.

The primary endpoint was time to first occurrence of CV death, non-fatal myocardial infarction (MI) or non-fatal stroke. Novo said Victoza demonstrated both non-inferiority and superiority to placebo on the endpoint, and said the superior reduction was driven by all three of the endpoint's components. ...